Aura Biosciences to Participate at the 42nd Annual Cowen Virtual Health Care Conference

Rhea-AI Summary

Aura Biosciences Inc. (NASDAQ: AURA), a biotechnology firm focused on innovative virus-like drug conjugate (VDC) therapies for cancer, announced CEO Elisabet de los Pinos will join a panel discussion on “Auditory and Ophthalmology” at the 42nd Annual Cowen Virtual Health Care conference on March 7, 2022, at 2:10 p.m. ET. A live webcast will be available on the company’s website, with a replay archived for 90 days. Aura’s lead candidate, AU-011, targets ocular cancers and is undergoing a Phase 2 clinical trial for choroidal melanoma, a severe eye cancer.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in the “Auditory and Ophthalmology” panel discussion at the 42^nd Annual Cowen Virtual Health Care conference taking place on Monday, March 7, 2022, at 2:10 p.m. Eastern Time.

A live webcast of the panel discussion will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences, Inc. (NASDAQ: AURA) is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is currently in development for ocular cancers, with an ongoing Phase 2 clinical trial evaluating first-line treatment of choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, leveraging Aura’s technology platform, Aura is developing AU-011 more broadly across multiple cancers, starting with a planned Phase 1a clinical trial in patients with non-muscle invasive bladder cancer. Aura is headquartered in Cambridge, MA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005296/en/

Investor and Media Contact:

Matthew DeYoung

Argot Partners

212-600-1902 | aura@argotpartners.com

Source: Aura Biosciences Inc.

FAQ

What is the date and time of the Cowen Virtual Health Care conference for Aura Biosciences?

The Cowen Virtual Health Care conference will take place on March 7, 2022, at 2:10 p.m. Eastern Time.

Where can I watch the Aura Biosciences panel discussion?

The panel discussion can be watched live on Aura Biosciences' 'Investors & Media' page under 'Events & Presentations' at their website.

What is the focus of Aura Biosciences' lead drug candidate AU-011?

AU-011 is focused on treating ocular cancers, particularly targeting choroidal melanoma.

What clinical trials is Aura Biosciences currently conducting?

Aura Biosciences is conducting a Phase 2 clinical trial for AU-011 in the treatment of choroidal melanoma and plans a Phase 1a trial for non-muscle invasive bladder cancer.